Overview

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Nanjing Leads Biolabs Co.,Ltd

Criteria

Inclusion Criteria:

1. Agree to comply with the trial treatment plan and visit plan, voluntarily agree to
sign the informed consent form;

2. 18-75 years old (including boundary value), no gender limit;

3. previous standard treatment failed, no standard treatment or standard treatment is not
applicable at this stage;

4. The expected survival time is at least 12 weeks

Exclusion Criteria:

1. Receiving other unmarketed clinical research drugs or treatments within 4 weeks before
using the research drug for the first time;

2. Brain parenchymal metastases or meningeal metastases with clinical symptoms, which are
not suitable for inclusion in the group by the investigator's judgment;

3. Women who are pregnant or breastfeeding;

4. The investigator believes that the subject has other conditions that may affect
compliance or are not suitable for participating in the study